Active, not recruitingPhase 1NCT05698017

Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early to Moderate Stage Multiple System Atrophy (MSA)

Studying Multiple system atrophy

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Cytora Ltd.
Intervention
hOMSC300(biological)
Enrollment
10 target
Eligibility
50-80 years · All sexes
Timeline
2022 – 2026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05698017 on ClinicalTrials.gov

Other trials for Multiple system atrophy

Additional recruiting or active studies for the same condition.

See all trials for Multiple system atrophy →

← Back to all trials